Revolutionizing Drug Development: The Patient Voice is Leading the Way!
Revolutionizing drug development is pivotal in today’s healthcare landscape, particularly as the patient voice grows louder and more influential in shaping therapies. The latest episode of Healthcare Rethink, a FinThrive podcast, looks at this transformative trend.
In an engaging discussion, host Brian Urban welcomes Wendy Erler, the VP of Global Patient Experience at Alexion and AstraZeneca, to explore the increasingly critical role of patient insights in drug development. Erler brings a unique perspective, having transitioned from a career in sales to a focus on patient advocacy, significantly impacting how drugs are developed and brought to market.
The conversation highlights Erler’s journey through various healthcare and pharmaceutical roles, leading to her current focus on rare disease communities. These groups are more than beneficiaries of drugs but also active participants in drug research and development, often driving the funding and direction of studies. Erler emphasizes that revolutionizing drug development today requires an ecosystem approach, where patients, caregivers, and families are integral to the conversation from the outset.
Erler and Urban discuss the balance between drug affordability and accessibility, a challenge that spans U.S. and global healthcare systems. Erler advocates for transparency and inclusivity in these discussions, ensuring patient experiences significantly influence drug development strategies. The dialogue extends into innovative partnerships and projects at AstraZeneca, where the integration of patient advocacy throughout the drug development process is ethical and strategic, ensuring that therapies are effective and aligned with patient needs.
